Riyadh Biotechnology Summit Concludes with SAR 5 Billion in Agreements

RIYADH, SAUDI ARABIA, Sept. 17, 2026 /CourierPR/ -- The Riyadh Global Medical Biotechnology Summit 2026 concluded on a high note, marking a significant milestone in Saudi Arabia's commitment to biotechnology. Over three days, the event attracted more than 15,000 visitors from over 57 countries, with more than 200 speakers across over 70 sessions. The ambition of the summit was translated into more than 40 agreements, initiatives, and announcements, with a combined declared value of more than SAR 5 billion (USD 1.33 billion), a substantial increase from the more than USD 100 million in deal value generated at the 2024 edition.

Partners from Spain, China, Japan, Germany, the United States, South Korea, Denmark, and Malaysia joined Saudi Arabia's leading universities, research centers, and manufacturers at the Sofitel Riyadh Hotel and Convention Centre. Over 120 sponsors and exhibitors filled 6,000 square meters of event space, and more than 180 strategic meetings took place.

The summit opened on September 14 under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, and was inaugurated by His Royal Highness Prince Abdullah bin Bandar bin Abdulaziz, Minister of National Guard. The event was also addressed by Her Royal Highness Princess Dr. Maha bint Mishari bin Abdulaziz Al Saud, Chief Executive Officer of the FII Institute, who highlighted the importance of capital, ideas, and long-term alliances in turning scientific breakthroughs into lasting impact on humanity.

The summit was built on four pillars: governmental strategies and regulatory support, investment and funding, research and development readiness, and building capabilities. Key agreements included the Vaccine Industrial Company's confirmation that its human vaccine manufacturing facility, a SAR 500 million investment across 42,000 square meters, is 85 percent complete and is planned to localize up to 80 percent of the Kingdom's essential vaccine needs.

In the realm of research and development, King Abdullah International Medical Research Center (KAIMRC) and Thermo Fisher Scientific announced a Center of Excellence for Genomics, Proteomics, and Biobanking. The University Hospitals Program at the Council of Universities' Affairs signed with Novo Nordisk to build clinical trial capability, including earlier phase trials. KAIMRC also agreed research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan's Chiyoda Corporation in plant-based peptide production for cancer treatment.

Efforts to build capabilities included KAIMRC's partnership with Rutgers University on a summer school, master's programs, and research in artificial intelligence, and with LeapUp on training and capacity building. Princess Nourah bint Abdulrahman University and Cellenkos launched a program to develop Saudi female talent in cell and gene therapy and biomanufacturing, and SVAX and Batterjee Medical College agreed on accredited biomanufacturing training with up to 350 seats per cycle. King Saud University launched four national initiatives, including an annual Saudi International Biotechnology Conference and the KSU BioHack hackathon.

The summit's success underscores Saudi Arabia's commitment to leading the field of biotechnology for decades to come. The National Biotechnology Strategy, launched by His Royal Highness the Crown Prince in January 2024, aims to contribute a USD 34.6 billion non-oil GDP from biotechnology by 2040. This achievement confirms the Kingdom's place at the forefront of global biotechnology.